ARQ Proprietary Ltd.

Schutte Named Interim CFO At Anooraq.
Investrend; 12/3/2009; 813 words; ...Anooraq Resources Corp. (TSX Venture: ARQ) (AMEX: ANO) has appointed De Wet...Renova Investments, Harmony Gold Mining Ltd. and Mittal Steel, with responsibilities...FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm...

Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference.
Business Wire; 11/16/2009; 1586 words; ...capabilities of the Company's proprietary drug discovery platform...efficiency of ArQule's proprietary, structure-based drug...Daiichi Sankyo Co., Ltd. About ArQule ArQule...clinical development, is ARQ 197, an inhibitor of...clinical testing with ARQ 621, designed to inhibit...

ArQule Announces Third Quarter Fiscal 2009 Results.(Financial report)
Business Wire; 11/5/2009; 2465 words; ...dose escalation trial with ARQ 621, an inhibitor of the...independent application of our proprietary kinase discovery technology...with Daiichi Sankyo Co., Ltd. continues to move forward...with Daiichi Sankyo Co., Ltd. for ARQ 197 and the AKIP[TM...

ArQule to Introduce Novel FGFR Inhibitor Program Discovered Through Its Proprietary Kinase Inhibitor Platform at AACR-NCI-EORTC Conference.(Conference news)
Business Wire; 10/15/2009; 1337 words; ...through the application of its proprietary ArQule Kinase Inhibitor Platform...with Daiichi Sankyo Co., Ltd., was announced in November...2 clinical development, is ARQ 197, an inhibitor of the c...Phase 1 clinical testing with ARQ 621, designed to inhibit the...

ArQule Expands Clinical Program With ARQ 197, c-Met Inhibitor.
Cancer Weekly; 3/17/2009; 1064 words; ...development program for ARQ 197, a proprietary, orally administered...and Daiichi Sankyo Co. Ltd. (TSE: 4568) signed...December 2008 to co-develop ARQ 197 (see also ArQule...clinical trial program for ARQ 197,o said Dr. Brian...